In cell studies and a xenograft model, this led to improved tumor cell killing and vascular remodeling when used in combination with other therapies such as gemcitabine and rapamycin.113, 114 Similarly, the compound YC-1 downregulated HIF-1α in a MAPK-signaling-dependent manner115 and inhibited HIF-driven transcription via stimulation of factor inhibiting HIF.116. This evidence concerns the gene HIF1A and neoplasm.